Assignee
XELLIA PHARMACEUTICALS APS
DK·24 granted patents·9 pending applications·45 citations·filing 2004–2024
Top patents by PatentIndex Score
33 records- 0194US11517609B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2022·Granted Dec 6, 2022·3 cites·7 claims
- 0293US11000567B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2019·Granted May 11, 2021·5 cites·28 claims
- 0393US10039804B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2017·Granted Aug 7, 2018·14 cites·17 claims
- 0492US10188697B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2015·Granted Jan 29, 2019·11 cites·26 claims
- 0591US10849956B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2018·Granted Dec 1, 2020·3 cites·24 claims
- 0687US11628200B2Glycopeptide compositionsXELLIA PHARMACEUTICALS APS·Filed 2021·Granted Apr 18, 2023·1 cites·18 claims
- 0783US12053502B2Daptomycin formulationsXELLIA PHARMACEUTICALS APS·Filed 2023·Granted Aug 6, 2024·1 cites·22 claims
- 0876US11925703B1Liquid composition comprising glucoseXELLIA PHARMACEUTICALS APS·Filed 2023·Granted Mar 12, 2024·0 cites·15 claims
- 0971US11759497B2Daptomycin formulationsXELLIA PHARMACEUTICALS APS·Filed 2018·Granted Sep 19, 2023·2 cites·14 claims
- 1071US9393307B2Caspofungin compositionXELLIA PHARMACEUTICALS APS·Filed 2014·Granted Jul 19, 2016·1 cites·19 claims
- 1165US2024139278A1Oxytocin formulationXELLIA PHARMACEUTICALS APS·Filed 2023·Application pending·0 cites
- 1263US11141417B2Voriconazole inclusion complexesXELLIA PHARMACEUTICALS APS·Filed 2019·Granted Oct 12, 2021·0 cites·19 claims
- 1362US12070485B2Liquid dalbavancin compositionsXELLIA PHARMACEUTICALS APS·Filed 2023·Granted Aug 27, 2024·0 cites·9 claims
- 1461US10933019B2Liquid formulations of daptomycinXELLIA PHARMACEUTICALS APS·Filed 2017·Granted Mar 2, 2021·2 cites·21 claims
- 1559US2024358792A1Liquid dalbavancin compositionsXELLIA PHARMACEUTICALS APS·Filed 2024·Application pending·0 cites
- 1657US2023255949A1Benzimidazole derivatives compositionsXELLIA PHARMACEUTICALS APS·Filed 2023·Application pending·0 cites
- 1756US10532080B2Sulfomethylated polymixin compositionsXELLIA PHARMACEUTICALS APS·Filed 2015·Granted Jan 14, 2020·1 cites·17 claims
- 1855US8048853B2Process for preparing pharmaceutical compound and intermediates thereofXELLIA PHARMACEUTICALS APS·Filed 2008·Granted Nov 1, 2011·1 cites·11 claims
- 1954US7919470B2Glycopeptide composition with improved antibiotic activityXELLIA PHARMACEUTICALS APS·Filed 2004·Granted Apr 5, 2011·0 cites·6 claims
- 2052US9067032B2Method for treatment of lung infections by administration of aminoglycosides by aerolisationXELLIA PHARMACEUTICALS APS·Filed 2013·Granted Jun 30, 2015·0 cites·18 claims
- 2150US10729708B2Stabilized glycopeptide antibiotic formulationsXELLIA PHARMACEUTICALS APS·Filed 2017·Granted Aug 4, 2020·0 cites·10 claims
- 2248US7868191B2Preparation and purification of mupirocin calciumXELLIA PHARMACEUTICALS APS·Filed 2007·Granted Jan 11, 2011·0 cites·19 claims
- 2347US2023068866A1Daptomycin formulationXELLIA PHARMACEUTICALS APS·Filed 2021·Application pending·0 cites
- 2446US7981859B2Glycopeptide composition with improved antibiotic activityXELLIA PHARMACEUTICALS APS·Filed 2004·Granted Jul 19, 2011·0 cites·10 claims
- 2545US2024083950A1Synthesis processXELLIA PHARMACEUTICALS APS·Filed 2022·Application pending·0 cites
- 2643US2022218784A1Daptomycin Aqueous FormulationsXELLIA PHARMACEUTICALS APS·Filed 2020·Application pending·0 cites
- 2741US10640536B2Polymyxins, compositions, methods of making and methods of useXELLIA PHARMACEUTICALS APS·Filed 2014·Granted May 5, 2020·0 cites·21 claims
- 2840US11033602B2Inhalation deviceXELLIA PHARMACEUTICALS APS·Filed 2015·Granted Jun 15, 2021·0 cites·17 claims
- 2940US2015352112A1Voriconazole inclusion complexesXELLIA PHARMACEUTICALS APS·Filed 2014·Application pending·0 cites
- 3037US10227371B2Polymorphs and new solid states of tiacumicin BXELLIA PHARMACEUTICALS APS·Filed 2015·Granted Mar 12, 2019·0 cites·2 claims
- 3137US2016031798A12-amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracinsXELLIA PHARMACEUTICALS APS·Filed 2015·Application pending·0 cites
- 3231US10711040B2Low substituted polymyxins and compositions thereofXELLIA PHARMACEUTICALS APS·Filed 2015·Granted Jul 14, 2020·0 cites·8 claims
- 3327US2016319318A1Process for the preparation of tiacumicinXELLIA PHARMACEUTICALS APS·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XELLIA PHARMACEUTICALS APS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →